JP2019504882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504882A5 JP2019504882A5 JP2018557209A JP2018557209A JP2019504882A5 JP 2019504882 A5 JP2019504882 A5 JP 2019504882A5 JP 2018557209 A JP2018557209 A JP 2018557209A JP 2018557209 A JP2018557209 A JP 2018557209A JP 2019504882 A5 JP2019504882 A5 JP 2019504882A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- histidine
- concentration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 9
- 229960002885 histidine Drugs 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 235000014633 carbohydrates Nutrition 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 239000002736 nonionic surfactant Substances 0.000 claims 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 206010047571 Visual impairment Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 229940068977 polysorbate 20 Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 208000029257 vision disease Diseases 0.000 claims 3
- 230000004393 visual impairment Effects 0.000 claims 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 229960002833 aflibercept Drugs 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 208000001309 degenerative myopia Diseases 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152767.6 | 2016-01-26 | ||
| EP16152767 | 2016-01-26 | ||
| EP16199497.5 | 2016-11-18 | ||
| EP16199497 | 2016-11-18 | ||
| PCT/EP2017/051662 WO2017129685A1 (en) | 2016-01-26 | 2017-01-26 | Liquid formulation of a vegf antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504882A JP2019504882A (ja) | 2019-02-21 |
| JP2019504882A5 true JP2019504882A5 (enExample) | 2019-12-12 |
| JP6953433B2 JP6953433B2 (ja) | 2021-10-27 |
Family
ID=57882094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557209A Active JP6953433B2 (ja) | 2016-01-26 | 2017-01-26 | Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10576128B2 (enExample) |
| EP (1) | EP3407868A1 (enExample) |
| JP (1) | JP6953433B2 (enExample) |
| AU (1) | AU2017213103B2 (enExample) |
| CA (1) | CA3011638C (enExample) |
| WO (1) | WO2017129685A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2944306T (pt) | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| US11692027B2 (en) | 2016-09-28 | 2023-07-04 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| JP7116059B2 (ja) * | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| IL315639A (en) | 2017-03-27 | 2024-11-01 | Regeneron Pharma | Sterilization method |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| MA50174A (fr) | 2017-09-18 | 2020-07-29 | Amgen Inc | Formules de protéines de fusion vegfr-fc |
| MA50908A (fr) | 2017-11-17 | 2020-09-23 | Amgen Inc | Formulations de protéines de fusion vegfr-fc |
| JP7183268B2 (ja) * | 2017-11-20 | 2022-12-05 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 |
| BR112020022610A2 (pt) | 2018-05-10 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | proteína de fusão de receptor de vegf de alta concentração que contém formulações |
| TWI866924B (zh) * | 2018-08-30 | 2024-12-21 | 美商再生元醫藥公司 | 用於將蛋白質複合物定特徵之方法 |
| KR20200029374A (ko) * | 2018-09-10 | 2020-03-18 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
| US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
| CA3114728C (en) * | 2018-10-29 | 2024-05-14 | F. Hoffmann-La Roche Ag | Antibody formulation |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| US11186625B2 (en) | 2019-12-06 | 2021-11-30 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| MX2022010951A (es) * | 2020-03-04 | 2022-10-07 | Shanghai Henlius Biotech Inc | Formulacion farmaceutica que comprende bevacizumab. |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN116096357A (zh) * | 2020-07-31 | 2023-05-09 | 赛特瑞恩股份有限公司 | 稳定的药物制剂 |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| WO2025217334A1 (en) * | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124449A (en) | 1990-06-11 | 2000-09-26 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US5731144A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
| US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| EP0828849B1 (en) | 1995-06-02 | 2006-10-25 | Gilead Sciences, Inc. | High-affinity oligonucleotide ligands to pdgf |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| BRPI0011407B8 (pt) | 1999-06-08 | 2021-05-25 | Regeneron Pharma | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| ES2633574T3 (es) * | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| PT2944306T (pt) * | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| EP3219294A1 (en) * | 2006-06-20 | 2017-09-20 | Ben-Gurion University of The Negev Research and Development Authority | Amphiphilic peptides and hydrogel matrices thereof for bone repair |
| CN110372792A (zh) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | 抑制vegf的稳定和可溶的抗体 |
| CN102272148A (zh) | 2008-11-03 | 2011-12-07 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP2854844A4 (en) | 2012-06-01 | 2016-11-23 | Ophthotech Corp | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US20150297675A1 (en) * | 2012-08-28 | 2015-10-22 | Aaron Osborne | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| JP2016522249A (ja) * | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用 |
| WO2015071348A1 (en) | 2013-11-18 | 2015-05-21 | Formycon Ag | Pharmaceutical composition of an anti-vegf antibody |
| EP3492495A1 (en) | 2014-05-12 | 2019-06-05 | Formycon AG | Pre-filled plastic syringe containing a vegf antagonist |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| WO2017085253A1 (en) | 2015-11-18 | 2017-05-26 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
-
2017
- 2017-01-26 AU AU2017213103A patent/AU2017213103B2/en active Active
- 2017-01-26 US US16/072,638 patent/US10576128B2/en active Active
- 2017-01-26 WO PCT/EP2017/051662 patent/WO2017129685A1/en not_active Ceased
- 2017-01-26 JP JP2018557209A patent/JP6953433B2/ja active Active
- 2017-01-26 EP EP17701350.5A patent/EP3407868A1/en active Pending
- 2017-01-26 CA CA3011638A patent/CA3011638C/en active Active
-
2020
- 2020-01-14 US US16/742,585 patent/US20200237862A1/en not_active Abandoned
-
2023
- 2023-02-23 US US18/173,549 patent/US20230248806A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504882A5 (enExample) | ||
| RU2722643C2 (ru) | Способ лечения болезней глаз | |
| Theodossiadis et al. | Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration | |
| JP2017536414A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| JP2021105051A (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| JP2015528454A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| JP2019510078A5 (enExample) | ||
| JP7081818B2 (ja) | 疾患治療のための抗体－薬剤相乗作用技術 | |
| JP2014532072A5 (enExample) | ||
| AR076796A1 (es) | Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento. | |
| RU2014129316A (ru) | Способы ингибирования глазного ангиогенеза | |
| JP2012525415A5 (enExample) | ||
| HRP20211453T1 (hr) | Liječenje amd uporabom aav sflt-1 | |
| HRP20170130T1 (hr) | Načini liječenja dijabetesa antagonistima gena dll4 | |
| CN102883738A (zh) | 治疗血管发生相关的眼部疾病的组合物和方法 | |
| EP2854760A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| JP2020532562A5 (enExample) | ||
| JP2015510882A5 (enExample) | ||
| CA3235778A1 (en) | Methods of use and administration of encapsulated cells | |
| Sharma et al. | Aflibercept—how does it compare with other anti-VEGF drugs | |
| RU2014126070A (ru) | Способы лечения и предотвращения глазных заболеваний | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| KR20220062279A (ko) | 안질환의 치료 방법 |